Fig. 5From: An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countriesPercentage of drugs for rare diseases publicly funded by province compared to regulators. AB, Alberta; BC, British Columbia; MB, Manitoba; NB, New Brunswick; NL, Newfoundland; NS, Nova Scotia; ON, Ontario; PE, Prince Edward Island; QC, Quebec; SK, SaskatchewanBack to article page